Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Median PS Value: ¥62.38 (As of Jul. 01, 2026) — 5324% Above Median


SHSE:600276 Jiangsu Hengrui Pharmaceuticals Co Ltd SHSE:600276
92 GF Score
Price ¥53.78
GF Value ¥60.44
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Jiangsu Hengrui Pharmaceuticals Co Median PS Value?

Jiangsu Hengrui Pharmaceuticals Co SHSE:600276 +3.34% 92 Median PS Value is ¥62.38 as of Jul. 01, 2026, which is 100% below its 10-year median of 1.15. GuruFocus rates SHSE:600276 with a GF Score™ of 92/100 and a GF Value™ of ¥60.44 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 544 Drug Manufacturers companies, Jiangsu Hengrui Pharmaceuticals Co ranks better than 50.18% on this metric.

This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Jiangsu Hengrui Pharmaceuticals Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ¥4.899. Jiangsu Hengrui Pharmaceuticals Co's 10-Year median PS Ratio is 12.7332. Therefore, the Median PS Value for today is ¥62.38.

As of today (2026-07-01), Jiangsu Hengrui Pharmaceuticals Co's share price is ¥53.78. Jiangsu Hengrui Pharmaceuticals Co's Median PS Value is ¥62.38. Therefore, Jiangsu Hengrui Pharmaceuticals Co's Price to Median PS Value for today is 0.86.

The historical rank and industry rank for Jiangsu Hengrui Pharmaceuticals Co's Median PS Value or its related term are showing as below:

SHSE:600276' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.78   Med: 1.15   Max: 2.09
Current: 0.86

During the past 13 years, the highest Price to Median PS Value of Jiangsu Hengrui Pharmaceuticals Co was 2.09. The lowest was 0.78. And the median was 1.15.

SHSE:600276's Price-to-Median-PS-Value is ranked better than
50.18% of 544 companies
in the Drug Manufacturers industry
Industry Median: 0.86 vs SHSE:600276: 0.86

Jiangsu Hengrui Pharmaceuticals Co  (SHSE:600276) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Jiangsu Hengrui Pharmaceuticals Co's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=53.78/62.38
=0.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jiangsu Hengrui Pharmaceuticals Co Median PS Value Related Terms


Jiangsu Hengrui Pharmaceuticals Co Median PS Value Historical Data

* Premium members only.

The historical data trend for Jiangsu Hengrui Pharmaceuticals Co's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangsu Hengrui Pharmaceuticals Co Median PS Value Chart

Jiangsu Hengrui Pharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 44.67 37.53 43.50 54.48 61.62

Jiangsu Hengrui Pharmaceuticals Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 57.40 58.67 60.79 61.62 62.38

SHSE:600276 vs ZTS, UTHR: Median PS Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Hengrui Pharmaceuticals Co's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jiangsu Hengrui Pharmaceuticals Co Price-to-Median-PS-Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jiangsu Hengrui Pharmaceuticals Co's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Jiangsu Hengrui Pharmaceuticals Co's Price-to-Median-PS-Value falls into.


SHSE:600276
92GF Score
Jiangsu Hengrui Pharmaceuticals Co Ltd SHSE:600276
Median PS Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jiangsu Hengrui Pharmaceuticals Co Median PS Value Calculation

Jiangsu Hengrui Pharmaceuticals Co's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=4.899*12.7332
=62.38

10-Year Median PS Ratio is 12.7332.
Jiangsu Hengrui Pharmaceuticals Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥4.899.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Median PS Value →
What does a Median PS Value of ¥62.38 mean?
Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) has a Median PS Value of ¥62.38 as of Jul. 01, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. This is 5324% above median its historical median of 1.15. Over the past decade, Jiangsu Hengrui Pharmaceuticals Co's Median PS Value has ranged from 0.78 to 2.09. According to the industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #271 out of 544 companies in the Drug Manufacturers industry, placing it in the top 49.8%.
Is Jiangsu Hengrui Pharmaceuticals Co's Median PS Value too high?
Jiangsu Hengrui Pharmaceuticals Co's current Median PS Value of ¥62.38 is 5324% above median its 10-year median of 1.15. Over the past 10 years, this metric has ranged from a low of 0.78 to a high of 2.09. Based on the distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #271 out of 544 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Jiangsu Hengrui Pharmaceuticals Co has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Hengrui Pharmaceuticals Co's Median PS Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #271 out of 544 companies for Median PS Value. This puts Jiangsu Hengrui Pharmaceuticals Co in the upper half of its industry. The industry median Median PS Value is 0.86. Historically, Jiangsu Hengrui Pharmaceuticals Co's own Median PS Value has ranged from 0.78 to 2.09 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.86, based on 544 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Hengrui Pharmaceuticals Co's current Median PS Value is ¥62.38, which is 5324% above median its own 10-year median of 1.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Hengrui Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥60.44, compared to a current price of ¥53.78 — trading 11% below its estimated fair value. The current Median PS Value is ¥62.38, which is 5324% above median its 10-year median of 1.15. Jiangsu Hengrui Pharmaceuticals Co's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276), the current Median PS Value is ¥62.38 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Overvalued in 2026?

Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co stock appears to be undervalued. The current stock price of ¥53.78 is trading 11% below its estimated GF Value™ of ¥60.44. GuruFocus considers Jiangsu Hengrui Pharmaceuticals Co to be Modestly Undervalued.

Key valuation signals for SHSE:600276:

  • Median PS Value: ¥62.38 (5324% above median its 10-year median of 1.15)
  • GF Value™: ¥60.44 vs. price of ¥53.78 (11% below fair value)
  • GF Score™: 92/100 with 1 warning sign

No single metric tells the full story. See the SHSE:600276 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jiangsu Hengrui Pharmaceuticals Co Business Description

Address No. 7, Kunlunshan Road, Economic and Technological Development Zone, Jiangsu Province, Lianyugang, CHN, 222000
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
92GF Score

Get the complete analysis for SHSE:600276

Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥53.78
Price
¥60.44
GF Value